Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2010 August;101(4) > Minerva Medica 2010 August;101(4):215-38

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

REVIEWS  CARDIOLOGY FORUM


Minerva Medica 2010 August;101(4):215-38

language: English

Antithrombotic treatment in acute coronary syndromes

Hoole S. P., Saw J.

Division of Cardiology Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada


PDF  


Platelet activation and thrombin formation are integral in the pathophysiology of acute coronary syndrome. Currently available pharmacotherapies inhibit the cascade of platelet aggregation and activation, and prevent thrombin formation to limit platelet-fibrin complex formation, thus maintaining coronary patency and ultimately improving clinical outcomes. This is a rapidly evolving field with next-generation antithrombotic combinations aimed at achieving the “Holy Grail” of improved anti-ischemic efficacy whilst minimizing bleeding risk. Our review article focuses on the use of antithrombotic agents for the contemporary management of patients with ACS.

top of page

Publication History

Cite this article as

Corresponding author e-mail

jsaw@interchange.ubc.ca